Table 1.

Antiproliferative activity of CUDC-305 in 40 human cancer cell lines

Cancer typeCell lineIC50 (μmol/L)
NSCLCA5490.70
NSCLCH19750.14
NSCLCH2920.22
NSCLCH21220.12
NSCLCCalu-60.15
NSCLCH19930.12
NSCLCH4600.16
NSCLCH17030.16
NSCLCH3580.20
GlioblastomaM59K0.67
GlioblastomaU118MG0.20
GlioblastomaLN180.17
GlioblastomaU87MG0.46
GlioblastomaU2510.29
Hepatic cancerHepG20.13
Hepatic cancerHep3B20.36
Gastric cancerN870.04
Colon cancerHCT-1160.81
Colon cancerWiDr0.16
Breast cancerMDA-MB-4680.14
Breast cancerBT-4740.14
Breast cancerSkBr30.37
Ovarian cancerOVCAR30.15
Ovarian cancerSKOV30.30
MesothelomaMSTO-211h0.42
Pancreatic cancerHPAC10.50
Pancreatic cancerBxPC30.52
Prostate cancerLnCap0.40
Prostate cancerPC-30.30
Renal cancerCaki0.90
SarcomaSK-ES-10.07
SarcomaSaos-20.22
SarcomaMNNG HDS0.44
MelanomaA3750.21
AMLHL-600.18
AMLMV4-110.10
CTCLMJ0.13
NHLPfeiffer0.57
NHLOPM-20.04
Multiple myelomaRPMI82260.32
  • Abbreviations: CTCL, cutaneous T-cell lymphoma; NHL, non–Hodgkins lymphoma.